Recommanded Product: 844501-71-9In 2012 ,《Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families》 was published in Bioorganic & Medicinal Chemistry Letters. The article was written by Curtin, Michael L.; Frey, Robin R.; Heyman, H. Robin; Soni, Niru B.; Marcotte, Patrick A.; Pease, Lori J.; Glaser, Keith B.; Magoc, Terrance J.; Tapang, Paul; Albert, Daniel H.; Osterling, Donald J.; Olson, Amanda M.; Bouska, Jennifer J.; Guan, Zhiwen; Preusser, Lee C.; Polakowski, James S.; Stewart, Kent D.; Tse, Chris; Davidsen, Steven K.; Michaelides, Michael R.. The article contains the following contents:
In an effort to identify multi-targeted kinase inhibitors with a novel spectrum of kinase activity, a screen of Abbott proprietary KDR inhibitors against a broad panel of kinases was conducted and revealed a series of thienopyridine ureas with promising activity against the Aurora kinases. Modification of the di-Ph urea and C7 moiety of these compounds provided potent inhibitors with good pharmacokinetic profiles that were efficacious in mouse tumor models after oral dosing. Compound 2 (ABT-348) of this series is currently undergoing Phase I clin. trials in solid and hematol. cancer populations.3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(cas: 844501-71-9Recommanded Product: 844501-71-9) was used in this study.
3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(cas: 844501-71-9) belongs to pyrazoles. Pyrazoles are commonly used scaffold molecules in drug discovery projects. The use of pyrazole derivatives is based on their analgesic, anti-inflammatory, antipyretic, antiarrhythmic, sedative, muscle relaxant, neuroleptic, anticonvulsant, monoamine oxidase inhibitory, antidiabetic and antibacterial activities. Recommanded Product: 844501-71-9
Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics